Lb Pharmaceuticals (LBRX) Income from Continuing Operations (2024 - 2026)
Lb Pharmaceuticals (LBRX) posted quarterly Income from Continuing Operations of 19054000.0 for Q1 2026, down 259.1% year-over-year from 11975897.18 in Q1 2025, and down 66.09% quarter-over-quarter from 11472000.0 in Q4 2025.
Powered by 
Analysis
Lb Pharmaceuticals (LBRX) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Lb Pharmaceuticals' Income from Continuing Operations history runs 3 years deep, the most recent figure standing at 19054000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 259.1% year-over-year to 19054000.0; the TTM figure through Mar 2026 stood at 39388000.0 (changed N/A YoY), while the FY2025 annual figure was 25205000.0, up 60.06% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 19054000.0, down from 11472000.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 3556000.0 in Q3 2025, with the low at 19054000.0 in Q1 2026.
- The 3-year median for Income from Continuing Operations is 8389000.0 (2025), against an average of 9773333.33.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations soared 74.92% in 2025, then sank 259.1% in 2026.
- Lb Pharmaceuticals' Income from Continuing Operations stood at 5071000.0 in 2024, then tumbled by 126.23% to 11472000.0 in 2025, then slumped by 66.09% to 19054000.0 in 2026.
- Business Quant data shows LBRX's Income from Continuing Operations at 19054000.0 in Q1 2026, 11472000.0 in Q4 2025, and 3556000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Lb Pharmaceuticals | 1.49 Bn | 1.49 Bn | - | -51.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -51.60 Mn |
| Mar 31, 2026 | -19.05 Mn |
| Dec 31, 2025 | -11.47 Mn |
| Sep 30, 2025 | -3.56 Mn |
| Jun 30, 2025 | -4.87 Mn |
| Mar 31, 2025 | -5.31 Mn |
| Dec 31, 2024 | -5.07 Mn |
| Sep 30, 2024 | -14.18 Mn |